Amyloid positive individuals with negative tau PET were demonstrated to less likely develop dementia in 5 years than those with positive tau imaging (Josephs et al., 2022), suggesting that tau pathology, in addition to glucose metabolism, could contribute to cognitive decline. The gene discussed is MAPT; the disease is Mental deterioration.